4.3 Article

Is COVID-19 a New Hematologic Disease?

Journal

STEM CELL REVIEWS AND REPORTS
Volume 17, Issue 1, Pages 4-8

Publisher

SPRINGER
DOI: 10.1007/s12015-020-09987-4

Keywords

SARS-CoV-2; Covid-19; Coagulopathy; D-dimers; Lymphopenia; Mesenchymal stem cells; Cytokine; Inflammation; Thrombosis; Stem cells

Funding

  1. French research national agency (Agence Nationale pour la Recherche) ANR SARCODO

Ask authors/readers for more resources

SARS-CoV-2 viruses are positive single-stranded RNA viruses that can lead to Covid-19, a respiratory infection with significant impact on the hematopoietic system and hemostasis, causing various cardiovascular complications. The medical community is exploring new treatment approaches for this infection, including targeted anti-inflammatory drugs and stem cell therapies, based on understanding Covid-19 pathophysiology, especially related to hematological disorders.
SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or stem cell therapies. A better understanding of Covid-19 pathophysiology, in particular hematological disorders, will help to choose appropriate treatment strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available